Pfizer, Merk report Q4 results: Citi's Geoff Meacham on key takeaways

Fizer and Merc reported earlier today. Join us right now with his reaction to the results is Jeff Meum. He's the head of healthcare research US pharmaceuticals and biotechnology at city.Good morning to you. Uh we've seen both of these stocks. Fizer down by the way 5%.Merc holding in a lot a lot better. But why don't we just go through the headlines here and what your your reaction was. >> Yeah. Yeah.Thanks Andrew for having me. Yeah, I would say for for Merc the guidance was a big worry going into uh the fo ...